Eli Lilly (NY:LLY)

1,143.12 +0.27 (+0.02%)

Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means ↗

April 28, 2026

Via MarketBeat

Is This Deal a Game Changer for Novo Nordisk? ↗

April 27, 2026

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Via The Motley Fool

Topics Artificial Intelligence

Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗

April 27, 2026

Eli Lilly has more to offer than some investors realize.

Via The Motley Fool

Should You Buy HIMS Stock Following Friday's Rally?

April 27, 2026

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Via Barchart.com

Should You Buy the Dip in Eli Lilly Stock Today?

April 27, 2026

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

Via Barchart.com

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 27, 2026

Via Get News

Topics Intellectual Property

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Is SpaceX Really Worth $1.75 Trillion -- or Is That Actually Too Low? ↗

April 27, 2026

This space stock could literally go "to the moon."

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering

Nuclear Is Back in a Big Way. Here Are 2 Stocks to Consider. ↗

April 26, 2026

With more focus on nuclear energy, companies connected to nuclear power could be strong long-term investments.

Via The Motley Fool

This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗

April 26, 2026

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

Via The Motley Fool

Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)? ↗

April 25, 2026

Eli Lilly is a giant in the weight-loss drug realm, and it's aiming to grow more.

Via The Motley Fool

Looking to Buy the Tech Turnaround? This Low-Cost Vanguard ETF Might Be Your Best Entry Point. ↗

April 25, 2026

You get the upside of the sector, while minimizing some of the risks.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗

April 25, 2026

The weight loss drug market may reach almost $100 billion in a few years.

Via The Motley Fool

Why Eli Lilly Stock Flopped on Friday ↗

April 24, 2026

High hopes for a freshly approved drug might not be realized, if early data is any indication.

Via The Motley Fool

Why Eli Lilly (LLY) Shares Are Trading Lower Today

April 24, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number...

Via StockStory

Topics Artificial Intelligence

Uncover the latest developments among S&P500 stocks in today's session. ↗

April 24, 2026

Via Chartmill

Deal Dispatch: QXO Nabs TopBuild For $17 Million, Voya Financial Urged To Evaluate Strategic Options, Pat McGrath Exits Chapter 11 ↗

April 24, 2026

Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs.

Via Benzinga

These S&P500 stocks are gapping in today's session ↗

April 24, 2026

Via Chartmill

Expert Matchmaker in Indianapolis Report by CX Research Institute

April 24, 2026

Via AB Newswire

Topics Economy

Battle Of The Weight-Loss Pills Continues With A Shocking Twist ↗

April 24, 2026

Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo.

Via Investor's Business Daily

This Vanguard Index Fund Could Turn $500 Per Month Into a $1.4 Million Portfolio as the AI Boom Unfolds ↗

April 24, 2026

Young adults with median earnings can build sizable portfolios by retirement by regularly purchasing shares of the Vanguard S&P 500 Growth ETF.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment

April 23, 2026

Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Vista Just Opened a $3 Million Position in Federated Hermes ↗

April 23, 2026

Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base.

Via The Motley Fool

Topics Regulatory Compliance

Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock?

April 23, 2026

Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?

Via Barchart.com

Topics Artificial Intelligence

Hims & Hers Jumps On Its New Eli Lilly-Tied Approach To Obesity ↗

April 23, 2026

Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs.

Via Investor's Business Daily

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗

April 23, 2026

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Via The Motley Fool

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗

April 23, 2026

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Via The Motley Fool

3 Healthcare Stocks With the Most Durable Competitive Moats ↗

April 23, 2026

These companies offer a clear path to sustained earnings growth.

Via The Motley Fool

Topics Intellectual Property

Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks

April 22, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.